Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: A long-term, randomized, placebo-controlled trial

International Clinical Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 11-24

  Katzman, Martin A ^a,b,c,d   Brawman Mintzer, Olga ^e   Reyes, Efren B ^f   Olausson, Bengt ^g   Liu, Sherry ^h   Eriksson, Hans ^g  

^a START Clinic for Mood and Anxiety Disorders   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d LAKEHEAD UNIVERSITY   (Canada)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f National Center for Mental Health   (Philippines)

^g ASTRAZENECA R AND D   (Sweden)

^h ASTRAZENECA   (United Kingdom)

Author keywords

generalized anxiety disorder; maintenance; quetiapine

Indexed keywords

QUETIAPINE;

ABNORMAL DREAMING; AGRANULOCYTOSIS; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DISTURBANCE; BACKACHE; BLADDER CANCER; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPEPSIA; EPILEPSY; FATIGUE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; INSOMNIA; INSULIN BLOOD LEVEL; IRRITABILITY; LETHARGY; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; PULSE RATE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTLESSNESS; RHINOPHARYNGITIS; RISK REDUCTION; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 78650809435     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833e34d9     Document Type: Article

References (63)

1. Allgulander C, Florea I, Huusom AK (2006). Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495-505.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
3. Andrews G, Sanderson K, Slade T, Issakidis C (2000). Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Organ 78:446-454.
4. Ansseau M, Fischler B, Dierick M, Mignon A, Leyman S (2005). Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 20:229-235.
5. Arvanitis LA, Miller BG, The Seroquel Trial 13 Study Group (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
6. Atkinson S, Khan A, Joyce M, Eggens I, Baldytcheva I, Brecher M (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetia-pine XR) monotherapy in patients with generalised anxiety disorder [abstract]. Int J Neuropsychopharmacol 11:277.
7. Baldwin DS, Nair RV (2005). Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother 5:443-449.
8. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596.
9. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J. WFSBP Task Force on Treatment Guidelines for Anxiety (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199.
10. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily mono-therapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychophar-macol 13:305-320.
11. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
12. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. (2007). Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord 101:27-34.
13. Bittner A, Goodwin RD, Wittchen HU, Beesdo K, Hofler M, Lieb R (2004). What characteristics of primary anxiety disorders predict subsequent major depressive disorder? J Clin Psychiatry 65:618-626. quiz.
14. Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A (2005). Quetia-pine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 66:73-79.
15. Brawman-Mintzer O, Knapp RG, Nietert PJ (2005). Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321-1325.
16. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193-213.
17. Canadian Psychiatric Association (2006). Management of anxiety disorders. Can J Psychiatry 51 (Suppl 2):1S-93S.
18. Carter RM, Wittchen HU, Pfister H, Kessler RC (2001). One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 13:78-88.
19. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, et al. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsycho-pharmacol 18:673-681.
20. Denys D, de Geus F, Van Megen HJ, Westenberg HG (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
21. DeVane CL, Chiao E, Franklin M, Kruep EJ (2005). Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. Am J Manag Care 11:S344-S353.
22. Devarajan S, Ali J, Dursun SM (2006). Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology (Berl) 185:402-403.
23. Dorée JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, Tourjman SV. (2007). Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 23:333-341.
24. Endicott J, Spitzer RL (1987). Schedule for affective disorders and schizophrenia (SADS). Acta Psychiatr Belg 87:361-516.
25. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
26. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18-28.
27. Flannery-Schroeder EC (2006). Reducing anxiety to prevent depression. Am J Prev Med 31:S136-S142.
28. Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, et al. (2005). Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 66:544.
29. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082-3088.
30. Goldstein JM, Christoph G, Grimm S, Liu J, Widzowski D, Brecher M (2007). Quetiapine's antidepressant properties: direct & indirect pharmacologic actions on norepinephrine & serotonin receptors. Eur Neuropsychopharma-col 17 (Suppl 4):S401.
31. Goldstein JM, Nyberg S, Brecher M (2008). Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. Eur Psychiatry 23 (Suppl 2):S202.
32. Guy W (1976). Abnormal involuntary movement scale (AIMS). In: Guy W, editor. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ no ADM 766-338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; pp. 534-537.
33. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
34. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2003). Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23:15-20.
35. Henning ER, Turk CL, Mennin DS, Fresco DM, Heimberg RG (2007). Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342-349.
36. Hoffman DL, Dukes EM, Wittchen H (2008). Human and economic burden of generalized anxiety disorder. Depress Anxiety 25:72-90. (Pubitemid 351213928)
37. Hoge EA, Worthington JJ III, Kaufman RE, Delong HR, Pollack MH, Simon NM (2008). Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 13:522-527.
38. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008). N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepress-ant activity. Neuropsychopharmacology 33:2303-2312.
39. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. (2008). Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22:1480-1486.
40. Kennedy SH, Lam RW, Cohen NL, Ravindran AV (2001). Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46 (Suppl 1):38S-58S.
41. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923.
42. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
43. Merideth CH, Cutler A, Neijber A, She F, Eriksson HA (2008). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder (GAD). Eur Neuropsychopharmacol 18:S499.
44. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
45. National Institutes of Mental Health (1970). CGI: clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU assessment battery. Chevy Chase: NIMH; pp. 1-6.
46. Nyberg S, Widzowski D, Goldstein MJ, Brecher M (2008). Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant, and mood-stabilizing properties of quetiapine. Poster presented at the 16th European Congress of Psychiatry, Nice, France, 5-9 April.
47. Pollack MH (2001). Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 62 (Suppl 19):20-25.
48. Pollack MH (2005). Comorbid anxiety and depression. J Clin Psychiatry 66 (Suppl 8):22-29.
49. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357. (Pubitemid 32545557)
50. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215.
51. Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884-895.
52. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749-756. (Pubitemid 41079609)
53. Sareen J, Cox BJ, Afifi TO, de GR, Asmundson GJ, ten HM, et al. (2005). Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 62:1249-1257. (Pubitemid 41586924)
54. Sheehan DV (1996). The anxiety disease. New York: Scribner.
55. Simon NM, Hoge EA, Fischmann D,Worthington JJ, Christian KM, Kinrys G, et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385.
56. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
57. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, et al. (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258.
58. Timdahl K, Carlsson A, Stening G (2007). An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 22:315-325.
59. Wittchen HU, Zhao S, Kessler RC, Eaton WW (1994). DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355-364.
60. Wittchen HU, Lieb R, Pfister H, Schuster P (2000). The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. Compr Psychiatry 41:122-132.
61. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002). Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8):24-34.
62. Yargic LI, Corapcioglu A, Kocabasoglu N, Erdogan A, Koroglu G, Yilmaz D (2004). A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract 8:205-211.
63. Yonkers KA, Warshaw MG, Massion AO, Keller MB (1996). Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 168:308-313.